1-9 of 9
Larry M. Karnitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A33: Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents

Arun Kanakkanthara, Catherine J. Huntoon, Xiaonan Hou, Minzhi Zhang, Ethan P Heinzen, Ann L. Oberg, John S. Weroha, Scott H. Kaufmann, Larry M. Karnitz
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A33.
https://doi.org/10.1158/1557-3265.OVCA19-A33
Published: 01 July 2020
View article titled, Abstract A33: Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents
Journal Articles

Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Jacob J. Kennedy, Shrabanti Chowdhury, Sara R. Savage, Xiaonan Hou, Catherine J. Huntoon, Richard G. Ivey, Qing Yu, Chenwei Lin, Dongqing Huang, Lei Zhao, Uliana J. Voytovich, Regine M. Schoenherr, Zahra Shire, Steven J. Skates, Jeffrey R. Whiteaker, Andrew N. Hoofnagle, Samuel C. Mok, Bing Zhang, Larry M. Karnitz, S. John Weroha, Steven P. Gygi, Scott H. Kaufmann, Pei Wang, Michael J. Birrer, Amanda G. Paulovich
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR02.
https://doi.org/10.1158/1557-3265.OVCA19-PR02
Published: 01 July 2020
View article titled, Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers
Journal Articles

Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER

Scott H. Kaufmann, Andrea E. Wahner Hendrickson, Maria I Harrell, Michael E. Menefee, Edward J. Tanner, David G Mutch, Elizabeth M. Swisher, Larry M. Karnitz
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): IS04.
https://doi.org/10.1158/1557-3265.OVCASYMP16-IS04
Published: 31 May 2017
View article titled, Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER
Journal Articles

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 899–907.
https://doi.org/10.1158/1078-0432.CCR-16-1274
Published: 14 February 2017
View article titled, A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Open the PDF for A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View article titled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract IA07: Targeting checkpoint signaling and DNA repair in ovarian cancer.

Larry M. Karnitz
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): IA07.
https://doi.org/10.1158/1557-3265.OVCA15-IA07
Published: 15 January 2016
View article titled, Abstract IA07: Targeting checkpoint signaling and DNA repair in ovarian cancer.
Journal Articles

Molecular Pathways: Targeting ATR in Cancer Therapy

Larry M. Karnitz, Lee Zou
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4780–4785.
https://doi.org/10.1158/1078-0432.CCR-15-0479
Published: 01 November 2015
View article titled, Molecular Pathways: Targeting ATR in Cancer Therapy
Open the PDF for Molecular Pathways: Targeting ATR in Cancer Therapy in another window
Journal Articles

Abstract POSTER-BIOL-1325: Ovarian cancer-associated CDK12 mutations disable its kinase activity and cause defects in homologous recombination

Poorval M. Joshi, Shari L. Sutor, Catherine J. Huntoon, Larry M. Karnitz
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-BIOL-1325.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-BIOL-1325
Published: 15 August 2015
View article titled, Abstract POSTER-BIOL-1325: Ovarian cancer-associated CDK12 mutations disable its kinase activity and cause defects in homologous recombination
Journal Articles

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, Brian D. Koh, Karen S. Flatten, Kevin L. Peterson, David Parry, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Larry M. Karnitz, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5364–5373.
https://doi.org/10.1158/1078-0432.CCR-12-0961
Published: 30 September 2012
View article titled, Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <em>In Vitro</em>
Open the PDF for Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <em>In Vitro</em> in another window
Includes: Supplementary data